nach oben

Erschienen in:

20.07.2019 | Original Contribution

Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?

verfasst von: Khadijeh Abhari, Saeede Saadati, Fatemeh Hosseini-Oskouiee, Zahra Yari, Hedayat Hosseini, Golbon Sohrab, Ehsan Hejazi, Shahram Agah, Amir Sadeghi, Azita Hekmatdoost

Erschienen in: European Journal of Nutrition | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to assess the superiority of low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet plus Bacillus coagulans supplementation to low FODMAP diet alone in the reduction of irritable bowel syndrome (IBS) symptoms.

Methods

In this randomized clinical trial, fifty IBS patients who met Rome IV criteria for IBS were randomly assigned to receive a low FODMAP diet plus either a probiotic or a placebo capsule for 8 weeks. Probiotic capsules contained 10⁹B. coagulans spores and 400 mg inulin, while placebo capsules consisted of 500 mg rice starch.

Results

Significant improvements were observed in abdominal pain intensity and frequency, abdominal distension, satisfaction with bowel habits, quality of life, defecation consistency, and patient-reported severity score in both groups; however, only improvement in severity score was significantly higher in probiotic group compared with placebo group (P = 0.001). Moreover, the frequency of patients with clinical improvement in IBS-symptom severity scale (IBS-SSS) was significantly more in probiotic group compared to placebo group (P = 0.038).

Conclusion

Our results indicate that the addition of probiotic supplement containing B. coagulans to the low FODMAP diet might be superior to low FODMAP diet in alleviating IBS symptoms.

Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM, for the ACGTFoMoIBS (2018) American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol 113(2):1–18. https://doi.org/10.1038/s41395-018-0084-x CrossRefPubMed

Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146(1):67-75.e65. https://doi.org/10.1053/j.gastro.2013.09.046 CrossRef

Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, Quigley EMM, Moayyedi P (2018) A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of Irritable Bowel Syndrome. Am J Gastroenterol 113(9):1290–1300. https://doi.org/10.1038/s41395-018-0195-4 CrossRefPubMed

Chen B, Kim JJ, Zhang Y, Du L, Dai N (2018) Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. https://doi.org/10.1007/s00535-018-1476-9 CrossRefPubMed

Parkes GC, Brostoff J, Whelan K, Sanderson JD (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103(6):1557CrossRef

Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109(10):1547–1561. https://doi.org/10.1038/ajg.2014.202(quiz 1546, 1562) CrossRefPubMed

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K (2017) A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: a randomized controlled trial. Gastroenterology 153(4):936–947. https://doi.org/10.1053/j.gastro.2017.06.010 CrossRefPubMed

Barbara G, Cremon C (2018) Probiotics in irritable bowel syndrome: where are we? Neurogastroenterol Motil 30(12):e13513. https://doi.org/10.1111/nmo.13513 CrossRefPubMed

Nyangale EP, Farmer S, Cash HA, Keller D, Chernoff D, Gibson GR (2015) Bacillus coagulans GBI-30, 6086 modulates Faecalibacterium prausnitzii in older men and women. J Nutr 145(7):1446–1452. https://doi.org/10.3945/jn.114.199802 CrossRefPubMed

10.

Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T (2018) Efficacy of Bacillus coagulans unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microb 9(4):563–572. https://doi.org/10.3920/bm2017.0129 CrossRef

11.

Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F (2018) Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res. https://doi.org/10.29219/fnr.v62.1218 CrossRefPubMedPubMedCentral

12.

Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK (2016) Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 15:21. https://doi.org/10.1186/s12937-016-0140-6 CrossRefPubMedPubMedCentral

13.

Drossman DA (2016) Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 150(6):1262–1279 (e1262) CrossRef

14.

Baron M (2009) A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 121(2):114–118CrossRef

15.

Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11(2):395–402CrossRef

16.

17.

Rogha M, Esfahani MZ, Zargarzadeh AH (2014) The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 7(3):156PubMedPubMedCentral

18.

Abhari K, Shekarforoush SS, Hosseinzadeh S, Nazifi S, Sajedianfard J (2015) The effects of prebiotic, probiotic and synbiotic diets containing Bacillus coagulans and inulin on serum lipid profile in the rat. Veterinary Science Development 5(2):5919

19.

Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK (2015) Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 15(1):21CrossRef

20.

Cruz-Aguliar RM, Wantia N, Clavel T, Vehreschild M, Buch T, Bajbouj M, Haller D, Busch D, Schmid RM, Stein-Thoeringer CK (2018) An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome patients reveals improvement in abdominal pain associated with the relative abundance of Akkermansia muciniphila. Neurogastroenterol Motil. https://doi.org/10.1111/nmo.13513 CrossRef

21.

Dolin B (2009) Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 31(10):655–659CrossRef

22.

Urgesi R, Casale C, Pistelli R, Rapaccini G, De Vitis I (2014) A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox^®) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 18(9):1344–1353PubMed

23.

Basturk A, Artan R, Yilmaz A (2016) Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol 27:439–443CrossRef

24.

Hun L (2009) Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 121(2):119–124CrossRef

25.

Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR (2009) A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC gastroenterology 9(1):85CrossRef

Titel: Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?
verfasst von: Khadijeh Abhari
Saeede Saadati
Fatemeh Hosseini-Oskouiee
Zahra Yari
Hedayat Hosseini
Golbon Sohrab
Ehsan Hejazi
Shahram Agah
Amir Sadeghi
Azita Hekmatdoost
Publikationsdatum: 20.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 5/2020
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-019-02060-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management?